Article
The cancer-specific lncRNA LISR customizes ribosomes to suppress anti-tumour immunity
medRxiv · 2024 · Cinque, S.; Verheyden, Y.; Adnane, S.; Marino, A.; Katopodi, V.; Demesmaeker, E.; Knezevic, Z.; Hanache, S.; Vendramin, R.; Cuomo, A.; Pozniak, J.; Calabuig, A. C.; Tabruyn, S.; Bechter, O.; Baietti, M. F.; Groaz, E.; Bonaldi, T.; Leucci, E.
Key facts
| Title | The cancer-specific lncRNA LISR customizes ribosomes to suppress anti-tumour immunity |
|---|---|
| First author | Cinque, S.; Verheyden, Y.; Adnane, S.; Marino, A.; Katopodi, V.; Demesmaeker, E.; Knezevic, Z.; Hanache, S.; Vendramin, R.; Cuomo, A.; Pozniak, J.; Calabuig, A. C.; Tabruyn, S.; Bechter, O.; Baietti, M. F.; Groaz, E.; Bonaldi, T.; Leucci, E. |
| Journal | medRxiv |
| Published | Jan 1, 2024 |
| DOI | 10.1101/2023.01.06.523012 |
| Devices mentioned | BK110039, DEN000008, K010696, K022086, K030408, K073490, K103302, K123955 |
| Product codes mentioned | CFN, GGL, GKZ, GTQ, JCI, KIP, KIT, MVU, NDS, NJT, OOI, PFF and 3 more |
At a glance
- 1–9 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1